Brukinsa (zanubrutinib) / Medison, BeiGene  >>  Phase 1
Welcome,         Profile    Billing    Logout  

21 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brukinsa (zanubrutinib) / BeiGene
BGB-3111_BGB-A317_Study_001, NCT02795182: Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Checkmark Presentation of data from trial in combination with tislelizumab in B-cell lymphoid malignancies at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from trial in combination with tislelizumab in B-cell lymphoid malignancies at ASH 2019
Completed
1b
75
RoW
Zanubrutinib, BGB-3111, Brukinsa, Tislelizumab, BGB-A317
BeiGene
Lymphoma, Leukemia
12/20
12/20
BGB-3111-103, NCT04163523: Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

Completed
1
18
RoW
Zanubrutinib, BGB-3111
BeiGene
Healthy Volunteers
07/16
07/16
BGB-3111-105, NCT04163783: Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Completed
1
6
US
[14C]-BGB-3111, BGB-3111
BeiGene
Healthy Volunteers
04/17
04/17
BGB-3111-104, NCT03301181: Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

Completed
1
40
US
BGB-3111 (Arm A), Rifampin, Rifadin, Rimactane, BGB-3111 (Arm B), Itraconazole, Sporanox, Orungal
BeiGene
Healthy Volunteers: Asian, Non-Asian
11/17
11/17
BGB-3111-106, NCT03432884: A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Completed
1
40
US
BGB-3111, Placebo, Moxifloxacin, Avelox
BeiGene
Healthy Volunteers
04/18
04/18
BGB-3111-108, NCT03561298: A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Completed
1
18
US
BGB-3111 and Drug Cocktail
BeiGene
Healthy Subjects
06/18
07/18
BGB-3111-107, NCT03465059: Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Completed
1
29
US
Zanubrutinib
BeiGene
Hepatic Insufficiency & Healthy Subjects
10/18
10/18
BGB-3111-1002, NCT03189524: A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

Checkmark Preliminary results in Chinese patients with B-Cell Lymphoma
Sep 2018 - Sep 2018: Preliminary results in Chinese patients with B-Cell Lymphoma
Completed
1
44
RoW
Zanubrutinib, BGB-3111
BeiGene
B-cell Lymphoma
08/20
08/20
BGB-3111_GA101_Study_001, NCT02569476: BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Checkmark P1 data in ASH 2017 [screenshot]
Dec 2017 - Dec 2017: P1 data in ASH 2017 [screenshot]
Checkmark Combination trial of BGB-3111+obinutuzumab in B-cell lymphoid malignancies
Jun 2017 - Jun 2017: Combination trial of BGB-3111+obinutuzumab in B-cell lymphoid malignancies
Completed
1
119
US, RoW
Zanubrutinib, BGB-3111, Obinutuzumab
BeiGene
B-cell Lymphoid Malignancies
09/20
09/20
BGB-3111-112, NCT04470908: The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Completed
1
13
US
Zanubrutinib, BGB-3111, Brukinsa, Rifabutin
BeiGene
Healthy, Male
11/20
11/20
BGB-3111-113 , NCT04551963: Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Completed
1
26
RoW
Zanubrutinib, BGB-3111, BRUKINSA, Fluconazole, Diltiazem, Voriconazole, Clarithromycin
BeiGene
B-cell Malignancies
02/22
02/22
NCT05547399: Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

Completed
1
43
US
Zanubrutinib, BGB-3111, Brukinsa
BeiGene
Healthy Volunteers
12/22
12/22
ME-401-002, NCT02914938: A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Terminated
1
97
Europe, US
ME-401, Rituximab, Rituxan, Zanubrutinib
MEI Pharma, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL)
03/23
03/23
NCT05767398: Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

Completed
1
58
US
Zanubrutinib, BGB-3111, Brukinsa
BeiGene
Healthy Volunteers
04/23
04/23
ChiCTR2200057058: A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With Rituximab In The Treatment Of Steroid-Ineffective Primary Immune Thrombocytopenia

Not yet recruiting
1
23
 
Zanubrutinib (80 mg, 2 times/day, for a total of 12 weeks) combined with Rituximab (375 mg/m2, 1 intravenous infusion) regimen
The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Kunming Medical University, The drug company offers zanubrutinib and rituximab
Primary Immune Thrombocytopenia
 
 
BGB-3111-110, NCT04436107: Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed
1
66
RoW
Zanubrutinib, BGB-3111, Lenalidomide
BeiGene
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/24
03/24
NCT04850495: Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Recruiting
1
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
Yazeed Sawalha
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
12/24
12/24
ZGR in TN CLL, NCT06547944: Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
1
30
RoW
Zanubrutinib, Lenalidomide, Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
12/25
12/26
PRT2527-02, NCT05665530: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Recruiting
1
274
Europe, Canada, US, RoW
PRT2527, Zanubrutinib, Venetoclax
Prelude Therapeutics, BeiGene
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
11/25
03/26
ChiCTR2200064195: A clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma

Recruiting
1
100
 
R-BAP chemotherapy regimen and zanubrutinib ;R-BAP chemotherapy regimen and Ibrutinib
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-raised
mantle cell lymphoma
 
 
BGB-11417-101, NCT04277637: Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Recruiting
1
537
Europe, US, RoW
BGB-11417, Sonrotoclax, Zanubrutinib, BGB-3111, obinutuzumab
BeiGene
Mature B-Cell Malignancies
08/27
08/27

Download Options